A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT

Bone Marrow Transplantation

Volumn 43, Issue 7, 2009, Pages 553-561

  Hebart, H ^a   Klingspor, L ^b   Klingebiel, T ^c   Loeffler, J ^d   Tollemar, J ^b   Ljungman, P ^b   Wandt, H ^e   Schaefer Eckart, K ^e   Dornbusch, H J ^f   Meisner, C ^a   Engel, C ^a   Stenger, N ^a   Mayer, T ^a   Ringden, O ^b   Einsele, H ^d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Dept Diagn Interventional Radiol   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; FLUCONAZOLE; NYSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HLA SYSTEM; HUMAN; INCIDENCE; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 64949149897     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.355     Document Type: Article

References (30)

1. Hebart H, Einsele H. Specific infectious complications after stem cell transplantation. Support Cancer Care 2004; 12: 80-85.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of literature. Clin Infect Dis 2001; 32: 358-366.
3. Viscoli C, Girmenia C, Marinus A, Colette L, Martino P, Vandercam B et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research andTreatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in haematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
5. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
6. Buckley HR, Richardson MD, Evans EGV, Wheat LJ. Immunodiagnosis of invasive fungal infection. J Med Vet Mycol 1991; 30 (Suppl 1): 249-260.
7. Duthie R, Denning DW. Aspergillus fungemia: Report of two cases andreview. Clin Infect Dis 1995; 20: 598-605.
8. Walsh TJ, Hathom JW, Sobel JD, Merz WG, Sanchez V, Märet S et al Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991; 324 1026-1031.
9. Walsh TJ, Lee JW, Sien T, Schaufele R, Bacher J, Switcheuko AC et al Serum D-arabinitol measuredby automated quantitative enzymatic assay for detection and therapeutic monitoring of experimental disseminated candidiasis: Correlation with tissue concentrations of candida albicans. J Med Vet Mycol 1994; 32: 205-215.
10. Gutierrez J, Maroto C, Piedrola G, Martin E, Perez JA. Circulating Candida antigens and antibodies: Useful markers of Candidemia. J Clin Microbiol 1993; 31: 2550-2552.
11. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
12. Hebart H, Löffler J, Reitze H, Engel A, Schumacher U, Klingebiel T et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: Implications for the management of febrile neutropenia. Br J Haematol 2000; 111: 635-640.
13. Florent M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie JP et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006; 193: 741-747.
14. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
15. Ringden O, Andström E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B in 187 transplant recipients treatedwith cyclosporin. Bone Marrow Transplant 1994; 14 (Suppl.): 10-14.
16. Mills W, Chopra K, Linch DC, Goldstone A. Liposomal amphotericin B in the treatment of fungal infectious in neutropenic patients: A single-centre experience of 133 episodes in 116 patients. Br J Haematol 1986; 86: 754-760.17
17. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal Amphotericin B for empirical therapy in patients with persistent fever andneutropenia. N Engl J Med 1999; 340 764-771.
18. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D et al A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
19. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B in Patients Infected with Fungi: Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
20. Loeffler J, Hebart H, Sepe S, Schumacher U, Klingebiel T, Einsele H. Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol 1998; 36: 275-279.
21. Einsele H, Hebart H, Roller G, Loeffler J, Rothenhoefer L, Mueller CA et al. Early detection and identification of Candida and Aspergillus species in bloodusing molecular probes. J Clin Microbiol 1997; 35: 1353-1360.
22. Ascioglu S, Rex JH, de Pauw B, Bennet JE, Bille J, Crokaert F et al Defining opportunistic invasive fungal infections in immunocompromisedpatients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 43: 7-14.
23. Meyers JD. Fungal infections in bone marrow transplant patients. Sem Oncol 1990; 17 (Suppl. 6): 10-13.
24. Verfaille C, Weisdorf D, Haake R, Hostetter M, Ramsay NKC, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-184.
25. Tollemar J, Ringden O, Bostrom L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-641.
26. Andström EE, Ringden O, Remberger M, Svahn BM, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996; 39: 185-193.
27. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
28. Francesconi A, Kasai M, Petraitiene R, Petraitis V, Kelaher AM, Schaufele R et al. Characterization and comparison of galactomannan enzyme immunoassay andquantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluidfrom experimental invasive pulmonary aspergillosis. J Clin Micribiol 2006; 44: 2475-2480.
29. Hummel M, Spiess B, Kentouche K, Niggemann S, Bohm C, Reuter S et al Detection of Aspergillus DNA in cerebrospinal fluid by a nested PCR assay in patients with cerebral aspergillosis. J Clin Microbiol 2006; 44: 3989-3993.
30. Klingspor L, Jalal S. Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect 2006; 12: 745-753.